| ID | 1355 |
| Name of the vaccine | HR5I |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 6 to 9 weeks |
| Description of the vaccine | Liquid hexavalent combination vaccine. |
| Name of the manufacturer | Merck Sharp & Dohme Corp. |
| Name of the manufacturing country | NA |
| Year of manufacture | 2003 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Four different formulations as primary series at 2, 3, 4, and booster at 12 to 14 months. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For acellular pertussis, tetanus, hepatitis B, diphtheria , inactivated poliovirus type 1, 2, and 3. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (4 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00551629 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|